Dale Muzzey
Chief Scientific Officer Myriad Genetics
Seminars
Wednesday 1st April 2026
Clinical Validation of Myriad Genetics’ Ultra-Sensitive pan-cancer WGS-based Precise MRD assay
8:50 am
- Understand how ultra-sensitive, tumor-informed MRD testing is being applied across clinical and development settings
- Walk away with a clear view of where ultra-sensitive MRD testing delivers value today and how to apply it across your own programs
